Cross-plots of (a) the proposed GPR, Ranjbar-Karaml et al. [14], Christaras et al. [52], Feng et al. [16], Gowida et al. [17] models and (b) Khandelwal et al. [13], Brandås et al.... by Fahd Saeed Alakbari (10701871)

Subjects:

Expression of non-muscle myosin (NM) IIC in skeletal muscle cells. by Hiroki Hamaguchi (22783780)

Subjects:

Comparison of soleus muscle weight and fiber size histogram between young and aged WT and NMIIC KO mice. by Hiroki Hamaguchi (22783780)

Subjects:

NMIIC expression and muscle weight in the soleus of 82-86-week-old mice. by Hiroki Hamaguchi (22783780)

Subjects:

Differentially-expressed NLR genes in susceptible T200 and tolerant TME3 genotypes infected with SACMV. by Bulelani L. Sizani (21485746)

Subjects:

Evaluation of mitochondrial protein expression and morphology in NMIIC KO mice. by Hiroki Hamaguchi (22783780)

Subjects:

Proliferation and differentiation of myoblasts derived from satellite cells in WT and NMIIC KO mice. by Hiroki Hamaguchi (22783780)

Subjects:

Expression profile of WRKY-TFs and ROS accumulation in susceptible T200 and tolerant TME3 cassava genotypes. by Bulelani L. Sizani (21485746)

Subjects:

Phenotypic characterization of NMIIC knockout (KO) mice. by Hiroki Hamaguchi (22783780)

Subjects:

Hypothetical model of the molecular mechanism underlying the ability of SACMV to suppress the host RNA silencing mechanism (PTGS) and systemic acquired resistance (SAR). by Bulelani L. Sizani (21485746)

Subjects:

Reinforced sample destruction mode. by Xiaoyan Ding (291429)

Subjects:

One-dimensional sand column test conditions. by Xiaoyan Ding (291429)

Subjects:

Total count of HiFi reads indicating gene variation in 24 cassava genotypes. by Bulelani L. Sizani (21485746)

Subjects:

COVID19 effect on essential services. by Admas Abera (11821659)

Subjects:

Fiber types and muscle force in the soleus of 18-20-week-old WT and NMIIC KO mice. by Hiroki Hamaguchi (22783780)

Subjects:

Phenotypic characterization of 81-week-old NMIIC KO mice. by Hiroki Hamaguchi (22783780)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”